1 / 15

Decisions of the Parties Related to Essential Use Nominations (EUNs) Ozone Secretariat 6 July 2008

Decisions of the Parties Related to Essential Use Nominations (EUNs) Ozone Secretariat 6 July 2008 Bangkok. HISTORY. Introduction of EU provision Copenhagen Adjustments and Amendment (1992, MOP4) 1 st decision - IV/25: criteria and process

waite
Download Presentation

Decisions of the Parties Related to Essential Use Nominations (EUNs) Ozone Secretariat 6 July 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Decisions of the Parties Related to Essential Use Nominations (EUNs) Ozone Secretariat 6 July 2008 Bangkok

  2. HISTORY • Introduction of EU provision • Copenhagen Adjustments and Amendment (1992, MOP4) • 1st decision - IV/25: criteria and process • 1st nominations – submitted at least 2yrs in advance of phase-out, 1 Jan 1996 • 1st exemptions – decision in 1994 for 1996/7 • Uses MDIs, space, L&A, fire fighting • Amounts 14,281T in 1996 (13,900T) ~700T (422T+286T EUN) for 2009 (560T) ~310T (130T+182T EUN) for 2010 (180T) Blue – MDI portions

  3. DECISIONS • Essential use criteria and process • IV/25; V/18; VI/9; VII/28; VII/34; VIII/9; X/6 • Essential use exemptions • V/14; VI/8; VI/9; VII/28; VIII/9; IX/18;X/6; XI/14; XII/9; XIII/8; XIV/4; XV/4 • XVI/12; XVII/5; XVIII/7; XIX/13 (criteria) • XVIII/8; XIX/14 (Russia aerospace) • MDIs • VI/9; VIII/10,11,12; IX/19; IX/20; XII/2; XIII/9,10; XIV/5; XV/5; XVII/14; XVIII/16 • Laboratory and Analytical uses • VI/9; Annex II MOP6 Rep; VII/11; VIII/9; IX/17; X/19; XI/15; XV/8; XVI/16; XVII/10; XIX/18

  4. Essential Use Process • Parties submit nominations for exemption the following year (multi-year OK) - 31 Jan{VII/9(8)} • EU Handbook of TEAP/MTOC guides the EUN preparation {V/18(5); VIII/10(11); XII/2(10); XV/5(9); XVI/12(2)} • TEAP review and recommendations – Progress Report - May{IV/25(3)(4); VII/34(5); VIII/9(8)} • Consideration by OEWG – July • Decisions for exemptions MOP – Nov/Dec • Parties submit accounting framework report - 31 Jan (next year){VIII/9(9)} • Emergency use exemption upto 20T {VIII/9(10)}

  5. Essential Use ProcessSome important details • Nominating Parties are to collate individual requests of companies {VII/28(2)} • Exemptions are approved as total CFCs, flexibility allowed between CFCs {X/6(5)} • Transfer of essential use authorization between Parties allowable {IX/20} and between MDI companies also allowable {XII/2(8)} • Essentiality of each use is annually reviewed by TEAP {IV/25(5)}

  6. Essential Use Criteria • It is necessary for the health, safety or is critical for society {IV/25(1a i)} • There are no available technically and economically feasible alternatives {IV/25(1a ii)} • All economically feasible steps have been taken to minimize use & emissions {IV/25(2b i)} • The substances are not available in sufficient quantity and quality from stocks {IV/25(1b ii)} • Any EU production should be additional to basic domestic needs for A5 {IV/25(1c)} • Use and emissions must be minimized {VI/9(4)}

  7. Further Criteria – MDI related • Any CFC-MDI product approved after 31 Dec 2000 in non-A5 NOT essential unless criteria in IV/25(1a) are met {XII/2(2), (1)} • No CFC to be authorized after MOP17 (2005) if non-A5 has no action plan for CFC-MDIs (salbu.) phaseout before 25OEWG {XV/5(4)} Action plan {XV/5(5)}: • Dates for ceasing CFCs for salbutamol-MDIs • Specific measures and actions for phase out • Measures to ensure CFC-MDIs supply to A5 where appr

  8. Further Criteria – MDI related • Parties (non-A5) to request companies requesting EU to demonstrate: • they are making effort on R&D of alternatives {VIII/10(1), XVIII/7(3), XIX/13(3)} • they are taking steps to assist the company’s MDI manufacturing facilities in A5/CEITs in upgrading and capital equipment {VIII/10(10)} • Parties (non-A5) when preparing EUNs, to consider stocks with the objective of maintaining no more than 1 yr’s supply {XVI/12(3), XVII(2), XVIII/7(2), XIX/13(2)}

  9. MDIs-related requests for EUNs • Nomination is to be accompanied by info on active ingredients, intended market and CFC amount for each use {XV/5(2)} • Party may submit in its nomination data aggregated by region and product group for CFC-MDIs intended for sale in A5 when more specific data are unavailable {XVI/12(2)}

  10. MDI Decisions - other key aspects • Concern for ‘smooth’ transition to non-CFC MDIs to ensure protection of public health and safety {VIII/10,11,12} • Actions by non-A5 to promote industry’s participation • Measures to facilitate transition • Info gathering on transition for non-A5s

  11. MDI Decisions – other key aspects • Requirement for non-A5 Parties with EUN to prepare national transition strategies for MDIs by 31 Jan 1999 latest {IX/19(5)} • A5 Parties encouraged to prepare national transition strategies {XII/12(6)} and ExCom requested to consider paying for this {XII/12(7)} • Annual reporting on the progress with implementation of the strategies {XII/12(5c)(6c)}

  12. MDI Decisions – other key aspects Request to ExCom to: • prepare guidelines for presentation of MDI projects in A5 Parties {XIII/9} • consider urgently the funding of projects for A5, MDI manufacturing Parties to facilitate their transition to non-CFC MDIs {XVIII/16(1)} • Review its decision 17/7 on cut-off date for MDI conversion projects consistent with pace of tech advances {XVIII/16(2)} • Consider including thematic regional workshops under UNEP’s agenda {XVIII/16(6)}

  13. MDI Decisions – other key aspects Request to non-A5 to • provide info/data for a global database on MDIs, both CFC and non-CFC, produced/exported/ imported, by active ingredient, brand/manufacturer, source/destination {XIV/4(1)} (39 Parties (22 A5) submitted data) • submit dates by which EUNs are to cease for MDIs where active ingredient is not solely salbutamol and where exported to non-A5 Parties {XV/5(6)} • Submit export manufacturing transition plan if manufacturing CFC MDIs for export where active ingredient is >10T {XVIII/16(7), (8), (9)}

  14. MDI Decisions – other key aspects • Request to ImpCom to consider how to address potential non-compliance of A5s from high CFC in MDI sector {XVIII/16(3)} & give special consideration {XVIII/16(4)} • Request to TEAP to: • Review and report on possible campaign production (non-A5) by April 1997 {VIII/9(7) i.e. 1996} • Assess and report on possible campaign production for A5 & non-A5 Parties by MOP19 {XVIII/16(12)}

  15. EU – Successful ProcessWell organizedEnsured smooth transitionHandbook THE END Thank you for your attention.

More Related